CClinicalTrials.gg
Not yet recruitingNCT07795372Updated Sep 2, 2026

Effect of Co-consuming Different Dietary Protein Sources With Salad on the Bioavailability of Carotenoids

An interventional study of Salad only and Salad + Chicken in Postprandial Carotenoid Response, sponsored by National University of Singapore. Not yet recruiting at 1 site in Singapore. Open to participants aged 21 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by National University of Singapore · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
21 Years to 45 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if different protein types will affect carotenoid responses in humans when co-consumed with salad. The main questions it aims to answer are:

  • What are the effect of dietary protein co-consumption with salad on postprandial carotenoid levels in Singapore adults?
  • Do different whole-food protein sources enhance the bioavailability of carotenoids in Singapore adults?

Participants will:

Consume salad with a form of protein (chicken, tuna, egg, soybean) Have their postprandial plasma carotenoid and triglyceride outcomes evaluated

Read the detailed description

This study will be a single-blind, randomized, crossover acute trial, and all participants will complete an approximately 3-month study period. A total of 19 participants will be recruited and go through all 5 arms (4 intervention and 1 control), with the order randomized. The study will comprise 1 screening visit and 5 test visits, with another 5 compliance visits.

02

Conditions studied

  • Postprandial Carotenoid Response

Keywords

  • Plasma carotenoid
  • Protein Type
03

Who can participate

Ages eligible
21 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. English-literate and able to give informed consent
  2. Singaporean Adults aged 21 to 45 (inclusive)
  3. Body mass index of 18.5 to 23.0 kg/m2 (inclusive)
  4. At least 50 kg
  5. Healthy (based on screening results)

Exclusion criteria

Exclusion Criteria:

  1. Currently participating in another clinical study that involves altering regular diet and/or involves consuming a dietary supplement or investigated food product as an intervention
  2. High blood pressure (≥ 140/90 mmHg)
  3. Underlying health conditions that may affect metabolic functions
  4. Consuming carotenoid supplements regularly (i.e., more than three times a week) for the past 3 months, and not willing to discontinue consumption 3 months before and during the study duration
  5. Weight change > 3 kg in the past 3 months
  6. Exercising vigorously over the past 3 months (i.e., engaging in high-intensity exercises for more than 3 hours a week, where high-intensity exercises leave one out of breath and unable to talk or sing during the workout)
  7. Current smokers or have quit smoking for less than 5 years
  8. Drinking > 2 alcoholic drinks per day (i.e., one drink is defined as either 150 ml of wine, 340 ml of beer/cider or 45 ml of distilled spirit)
  9. If drinking ≤ 2 alcoholic drinks per day, not willing to stop consumption of alcoholic beverages two days before and on the day of the test visits
  10. Not willing to stop consumption of caffeinated beverages 10 to 12 hours before and on the day of the test visits
  11. Currently on a specialised diet (e.g., vegetarian, vegan, weight loss diet)
  12. Had serious food allergies in the past, or having intolerance, sensitivities or allergies to any of the following: soy/soy-derived products, eggs, fish and crustaceans, starch/starch-derived products (e.g., rice, corn, wheat, potato), gluten
  13. Disease or impairment of the liver
  14. Currently diagnosed with diabetes, gastrointestinal issues (e.g., lactose intolerance, irritable bowel syndrome), gout and/or G6PD deficiency
  15. Taking antibiotics 2 weeks prior to study participation
  16. Taking anti-hypertensive or cholesterol-lowering drugs for less than 3 years unless medically declared by an official doctor to be in stable condition
  17. Poor peripheral venous access based on past experiences with blood drawing
  18. Individuals with pacemaker or related electrical medical devices
  19. Pregnant, lactating, or planning pregnancy in the next 6 months
  20. Have donated blood (whole blood or apheresis) or participated in any other clinical study or trial requiring blood draws within the last 3 months
  21. Clinical anemia (hemoglobin \<12.0 g/dL in women and \<13.0 g/dL in men)
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
19 participants (estimated)

Study arms

  • Placebo comparator
    Salad only

    Salad only (no protein)

    Other: Salad only

  • Experimental
    Salad + Chicken

    Salad with chicken

    Other: Salad + Chicken

  • Experimental
    Salad + Tuna

    Salad with tuna

    Other: Salad + Tuna

  • Experimental
    Salad + Egg

    Salad with egg

    Other: Salad + Egg

  • Experimental
    Salad + Soybean

    Salad with soybeans

    Other: Salad + Soybean

Interventions

  • OtherSalad only

    Control group, consumption of only salad

  • OtherSalad + Chicken

    Consumption of salad with chicken

  • OtherSalad + Tuna

    Consumption of salad with tuna

  • OtherSalad + Egg

    Consumption of salad with egg

  • OtherSalad + Soybean

    Consumption of salad with soybean

05

What researchers measure

Primary outcomes

  1. Concentration of plasma carotenoids

    Concentration of plasma carotenoids hourly

    Time frame: From start of salad consumption to the end of acute period (8 hours)

  2. Concentration of blood triglycerides

    Postprandial triglyceride response

    Time frame: From start of salad consumption to the end of acute period (8 hours)

06

Study locations

1 site
  • NUS, Department of Food Science and Technology, 1 Science Drive 3, Block S13, #03-07, Singapore, 117542
    Singapore, 117542, Singapore
    • Wei Xi Khu, B.Sc. · Contact · E0773498@u.nus.edu · +65 93598952
    • Jung Eun Kim, Ph.D., R.D. · Principal investigator
07

References and documents

Individual participant data

Plan to share: No — Electronic copies of the data with identifiable participant information will be kept on NUS OneDrive with access limited only to Dr Kim Jung Eun and her research staff. All data will be de-identified prior to statistical analyses.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07795372
Lead sponsor
National University of Singapore
Responsible party
Jung Eun Kim (Associate Professor, National University of Singapore) — Principal investigator
First posted
Aug 31, 2026
Start date
Sep 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Wei Xi Khu, B.Sc.
Contact
E0773498@u.nus.edu
+65 9359 8952
Jung Eun Kim, Ph.D., R.D.
principal investigator · National University of Singapore, Department of Food Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion